If I had to pick one stock for my watchlist, I’d go with $Dell Technologies Inc.(DELL)$ . Record AI server orders and a massive backlog show that enterprise AI capex remains strong. If AI infrastructure demand continues expanding, I believe DELL still has room for further earnings upgrades. That said, I wouldn’t chase it simply because it’s at a new high. Much of the AI growth story may already be priced in, so I’d watch order growth, margins and backlog conversion. A pullback without fundamental deterioration could offer a better entry. I also like $Halozyme Therapeutics(HALO)$ and
POLL>>🪙 | 💰 6 US Stocks Hit New Highs: DELL, BNY, RPRX, UNM, HALO,...
💬 Join the discussion: Vote in our poll below and share your take in the comments — every useful comment earns Tiger Coins! 🎁 Six U.S. stocks with market caps above $10 billion are trading at fresh all-time highs as of September 4, 2026. The top 6 span AI-driven enterprise hardware, global custody banking, biopharmaceutical royalty aggregation, workplace life and disability insurance, drug-delivery royalty licensing, and Latin American integrated steel — alongside one large-cap PC/server maker at the center of the group. This spread points to an AI infrastructure capex supercycle (record order backlogs and triple-digit EPS growth at the hardware leader), broad-based strength in fee-driven financials and insurers (record custody assets, double-digit fee growth, and rising capital return), r
Now, with just 100 bucks, you can snag shares of $AT&T Inc(T)$ and $Royalty Pharma plc(RPRX)$ . If you've got the cash to spare and don’t have bills to worry about, sinking it into these stocks for the long haul is almost a surefire way to keep that passive income ticking upward.1. $AT&T Inc(T)$AT&T is a no-brainer dividend stock worth grabbing for $100. With the recent price, this telecom giant yields a meaty 5.1%. They trimmed their dividend in 2022 and haven’t bumped it up again yet, but a return to those yearly high payouts feels just around the corner.Just this September 30, AT&T announced a deal to offload the remainder of their DirecTV shares to
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.